Extended Protocol (24 Weeks): The longest clinical trial evaluated 24-week daily administration with doses of 0.25 mg, 0.5 mg, and 1 mg
Neurological benefits including improved outcomes in demyelinating disease models point to CNS effects
Kennedy himself acknowledged this directly, stating that the restrictions created the gray market. Removal from Category 2 is a step toward potentially restoring safe, regulated access, depending on what the PCAC review concludes in July
Angiogenesis (Blood Vessel Formation): It promotes the formation of new blood vessels by stimulating VEGF (vascular endothelial growth factor), enhancing wound healing
MOTS-c supports mitochondrial membrane potential and ATP production under oxidative-stress challenges
Adding 2mL creates a 2.5mg/mL solution where the 0.25mg starting dose equals exactly 10 units and the maximum common dose of 2.5mg fills the entire 100-unit syringe